Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
45.32
+1.31 (2.98%)
At close: Apr 23, 2025, 4:00 PM
45.15
-0.17 (-0.38%)
After-hours: Apr 23, 2025, 4:05 PM EDT
Disc Medicine Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Disc Medicine stock have an average target of 83.8, with a low estimate of 43 and a high estimate of 132. The average target predicts an increase of 84.91% from the current stock price of 45.32.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 18, 2025.
Analyst Ratings
The average analyst rating for Disc Medicine stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $99 → $132 | Buy | Maintains | $99 → $132 | +191.26% | Mar 18, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $85 | Buy | Initiates | $85 | +87.56% | Mar 7, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $73 → $75 | Buy | Maintains | $73 → $75 | +65.49% | Mar 3, 2025 |
| Stifel | Stifel | Strong Buy Maintains $90 → $94 | Strong Buy | Maintains | $90 → $94 | +107.41% | Jan 24, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $70 → $73 | Buy | Maintains | $70 → $73 | +61.08% | Jan 22, 2025 |
Financial Forecast
Revenue This Year
n/a
from 447.96M
Revenue Next Year
n/a
EPS This Year
-5.01
from -3.96
EPS Next Year
-5.03
from -5.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 57.8M | 195.3M | ||
| Avg | n/a | 30.1M | 118.1M | ||
| Low | n/a | n/a | 9.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 548.8% | ||
| Avg | - | - | 292.6% | ||
| Low | - | - | -67.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.88 | -3.74 | -1.43 | ||
| Avg | -5.01 | -5.03 | -4.24 | ||
| Low | -5.82 | -7.55 | -8.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.